Maze Therapeutics

MAZE · NASDAQ

$32.45+$2.75 (+9.26%)TodayMarket closed ·
Prev close $29.70

Latest news

  • Press releaseGlobe Newswire

    Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Maze Therapeutics Announces Appointments to Its Board of Directors

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

  • Press releaseGlobe Newswire

    Maze Therapeutics Announces $150 Million Registered Offering

  • NewsAvi Kapoor

    Crude Oil Moves Lower; Cintas Raises FY2026 Forecast

  • NewsAvi Kapoor

    Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    Earnings Scheduled For March 25, 2026

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

  • Press releaseGlobe Newswire

    Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

  • Press releasePRNewswire

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

  • Press releaseGlobe Newswire

    Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

  • NewsVandana Singh

    Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • NewsAvi Kapoor

    This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

  • NewsAvi Kapoor

    Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.